Taxonomic group: bacteria / Spirochaetes
(Phylum: Spirochaetes)
Host organism: Homo sapiens
Associated disease: Lyme disease [ICD11:
1C1G 
, ICD11:
XN13C ];
infection due to Borrelia garinii [ICD11:
XN4VZ ];
infection due to Borrelia afzelii [ICD11:
XN7GL ]
The structure was elucidated in this paperNCBI PubMed ID: 19307181Publication DOI: 10.1074/jbc.M809575200Journal NLM ID: 2985121RPublisher: Baltimore, MD: American Society for Biochemistry and Molecular Biology
Correspondence: nicolas.schroeder
charite.de
Institutions: Division of Immunochemistry, Research Center Borstel, Borstel, Germany, Institute for Microbiology and Hygiene, Charité Medical Center, Berlin, Germany, Bavarian Health and Food Safety Authority, Oberschleissheim, Germany, Max von Pettenkofer-Institute for Medical Microbiology and Hygiene, Ludwig-Maximilian University, Munich, Germany, Institute for Neuropathology, Charité Medical Center, Berlin, Germany
Borrelia burgdorferi sensu lato is the causative agent of Lyme disease (LD), an infectious disease occurring in North America, Europe, and Asia in different clinical stages. B. burgdorferi sensu lato encompasses at least 12 species, with B. burgdorferi sensu stricto, B. garinii, and B. afzelii being of highest clinical importance. Immunologic testing for LD as well as recent vaccination strategies exclusively refer to proteinaceous antigens. However, B. burgdorferi sensu stricto exhibits glycolipid antigens, including 6-O-acylated cholesteryl β-D-galactopyranoside (ACGal), and first the data indicated that this compound may act as an immunogen. Here we investigated whether B. garinii and B. afzelii also possess this antigen, and whether antibodies directed against these compounds are abundant among patients suffering from different stages of LD. Gas-liquid chromatography/mass spectroscopy and NMR spectroscopy showed that both B. garinii and B. afzelii exhibit ACGal in high quantities. In contrast, B. hermsii causing relapsing fever features 6-O-acylated cholesteryl β-D-glucopyranoside (ACGlc). Sera derived from patients diagnosed for LD contained antibodies against ACGal, with 80% of patients suffering from late stage disease exhibiting this feature. Antibodies reacted with ACGal from all three B. burgdorferi species tested, but not with ACGlc from B. hermsii. These data show that ACGal is present in all clinically important B. burgdorferi species, and that specific antibodies against this compound are frequently found during LD. ACGal may thus be an interesting tool for improving diagnostics as well as for novel vaccination strategies.
glycolipid, Borrelia burgdorferi, Lyme disease, galactoside
Structure type: monomer
Location inside paper: Fig.3, ACGal, Fig.2
Compound class: glycolipid, glycoside
Contained glycoepitopes: IEDB_136044,IEDB_137472,IEDB_141181,IEDB_141794,IEDB_153297,IEDB_153298,IEDB_187036,IEDB_190606,IEDB_534865,SB_165,SB_166,SB_187,SB_195,SB_7,SB_88
Methods: 13C NMR, 1H NMR, GLC-MS, NMR-2D, DNA sequencing, TLC, GLC, biological assays, serological methods, immunoblotting, CC, cell growth, sonication, DEPT, centrifugation
Related record ID(s): 45788, 45789, 45790, 45791
NCBI Taxonomy refs (TaxIDs): 224326,
29519,
390236
Show glycosyltransferases
There is only one chemically distinct structure:
Found 
report error
(later renamed to: Borreliella burgdorferi B31 ATCC 35210)